Title |
Use of cognitive enhancers for mild cognitive impairment: protocol for a systematic review and network meta-analysis
|
---|---|
Published in |
Systematic Reviews, May 2012
|
DOI | 10.1186/2046-4053-1-25 |
Pubmed ID | |
Authors |
Andrea C Tricco, Charlene Soobiah, Erin Lillie, Laure Perrier, Maggie H Chen, Brenda Hemmelgarn, Sumit R Majumdar, Sharon E Straus |
Abstract |
Elderly individuals who have memory problems without significant limitations in activities of daily living are often diagnosed as having mild cognitive impairment (MCI). Some of these individuals progress to dementia. Several cognitive enhancers (for example donepezil, galantamine, rivastigmine, memantine) have been approved for use in people with Alzheimer's dementia but their use in patients with MCI is unclear. We aimed to determine the comparative effectiveness, safety, and cost of cognitive enhancers for MCI through a systematic review and network (that is, indirect comparisons) meta-analysis. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 40% |
Venezuela, Bolivarian Republic of | 1 | 20% |
United Kingdom | 1 | 20% |
Italy | 1 | 20% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 80% |
Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Indonesia | 1 | <1% |
Iran, Islamic Republic of | 1 | <1% |
United States | 1 | <1% |
Canada | 1 | <1% |
Unknown | 125 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 20 | 16% |
Student > Bachelor | 15 | 12% |
Student > Ph. D. Student | 14 | 11% |
Student > Master | 14 | 11% |
Student > Postgraduate | 10 | 8% |
Other | 28 | 22% |
Unknown | 28 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 33 | 26% |
Psychology | 22 | 17% |
Nursing and Health Professions | 10 | 8% |
Neuroscience | 6 | 5% |
Economics, Econometrics and Finance | 5 | 4% |
Other | 22 | 17% |
Unknown | 31 | 24% |